Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
See Latest ArticlesThe Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours
Clinical and Experimental Immunology, 10/06/09
Yang H et al. – The results suggest that the recombinant N–terminal part of MUC1, which may provide a diverse epitope repertoire, could be utilized as an effective tumour antigen for DC–based cancer immunotherapy.
Related Articles
The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer
Acta Oncologica, 11/02/09
Relevance Score: 95%
Cutaneous metastasis from gastric glomus tumour
Clinical and Experimental Dermatology, 10/05/09
Relevance Score: 92%
Juxtarenal/pararenal Wilms’ tumour in a six-year-old Malay girl
Singapore Medical Journal, 10/05/09
Relevance Score: 92%
Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: Results of the first UKCCSG/SIOP CNS 9204 trial
European Journal of Cancer, 10/13/09
Relevance Score: 91%
Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming
Immunology, 10/12/09
Relevance Score: 91%
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
IL-13 from Th2-type cells suppresses induction of antigen-specific Th1 immunity in a T-cell lymphoma
International Immunology, 12/03/09
Prioritization of cancer antigens: keeping the target in sight
Expert Review of Vaccines, 12/02/09
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Clinical Cancer Research, 12/01/09
Sponsor
Article Search
Sponsor